Innovation Theater Lunch (non-accredited/non-approved for CECH): Second Landmark RCT Evaluating Mirragen in Diabetic Foot Ulcers

Sponsored by Engineered Tissue Solutions (ETS).

In a prospective, multi-centered randomized controlled trial (RCT) involving 100+ patients, wound care physicians evaluated the impact of Mirragen, a borate-based bioactive glass fiber matrix, in the treatment of diabetic foot ulcers (DFUs). The second RCT on DFUs sponsored by Engineered Tissue Solutions (ETS) further illustrates Mirragen’s ability to facilitate the wound healing process in these challenging wounds.

Join us for our lunch symposium, where top wound care experts will delve into the study’s details and explore why Mirragen is an essential addition to your wound care armamentarium.